As of March 9, South Korea with a population of 51 million, tested 210,000 for the Wuhan virus - or about 0.4% of the population. They have been touted as the vanguard of rapid testing.
But what did this small slice of population testing really do to reduce the spread in Korea? Probably nothing. Obviously, they would not have identified any of the other 99.6% of their population that may have been infected.
Quickly closing borders from infected countries and calling for social distancing was the only thing that might influence the trajectory of the virus. The number of fatalities will also depend on the health care system and the ability to rapidly administer advanced medicines in the short term. European countries like Italy are learning about what socialized health care does to the fatality rate of elders.
More testing may help countries understand that the real numbers of fatalities are much lower than previously reported because many have minor symptoms and it could help to understand the nature of the virus, but it had no value in stopping the spread of the virus.
Developing tests to verify that you have defeated the Wuhan virus may allow people to go back to work sooner. These tests may be available in the short term and are important.
We have a number of drugs currently being used for other applications that show the ability to mitigate the severity of the Wuhan virus and significantly reduce fatalities and should be approved by the FDA as soon as possible for critical cases.
It will be interesting to see how the typical seasonal flu virus versus the Wuhan virus will compare in the US and other countries based on fatalities this year.
The vaccination for the Wuhan virus is probably a year away. But given that your seasonal flu vaccination can sometimes only be 40% effective, who knows.